Clinical Scorecard: Anticipated Effects of Interreader Variability in MRI-Guided Biopsy Among Uropathologists on the ProScreen Prostate Cancer Screening Trial: A Validation Study Prior to Trial Initiation

At a Glance

Key Highlights

• mpMRI-targeted biopsies improve detection of clinically significant prostate cancer and reduce diagnosis of clinically insignificant cases compared to systematic biopsies.
• Interreader variability among uropathologists interpreting MRI-targeted prostate biopsies is substantial, with complete agreement in only 21.2% of cases and consensus (≥2/3 agreement) in 65.9%.
• Accurate pathological grading of MRI-targeted biopsies is critical for appropriate treatment selection and minimizing overdiagnosis in prostate cancer screening trials like ProScreen.

Guideline-Based Recommendations

Diagnosis

• Use mpMRI to identify suspicious prostate lesions (PI-RADS 3–5) prior to biopsy.
• Perform targeted prostate biopsies of MRI-visible lesions using MRI-fusion techniques.
• Pathologists should follow current ISUP guidelines when grading MRI-targeted prostate biopsies.

Management

• Focus on detecting clinically significant prostate cancer to guide treatment decisions and reduce overtreatment of clinically insignificant disease.
• Use consensus pathology grading to inform clinical management in screening trials.

Monitoring & Follow-up

• Monitor interobserver agreement among pathologists to ensure consistency in biopsy interpretation.
• Evaluate biopsy grading reproducibility as part of quality control in prostate cancer screening programs.

Risks

• Interreader variability may lead to inconsistent grading and potential misclassification of prostate cancer severity.
• Overdiagnosis and overtreatment of clinically insignificant prostate cancer remain concerns without accurate pathological assessment.

Patient & Prescribing Data

Men undergoing prostate cancer screening with elevated PSA and MRI-targeted biopsies

Accurate pathological grading of MRI-targeted biopsies is essential to distinguish clinically significant cancers that require treatment from insignificant cancers that may be monitored.

Clinical Best Practices

• Implement standardized pathology protocols and training for interpreting MRI-targeted prostate biopsies to reduce interreader variability.
• Use consensus grading approaches (≥2/3 agreement) to improve diagnostic reliability in clinical trials and practice.
• Incorporate mpMRI and targeted biopsy strategies in population-based prostate cancer screening to balance mortality reduction with minimization of overdiagnosis.

References

• Eklund et al., 2020 - MRI-targeted biopsy vs systematic biopsy in prostate cancer detection
• ISUP Consensus Conference on prostate biopsy reporting
• ProScreen Trial Protocol